Hyderabad: Global pharma major Lupin Limited (Lupin) today announced that its European hub entity, Lupin Atlantis Holdings SA, has completed the acquisition of two well-known brands, Aarane in Germany and Nalcrom in Canada and the Netherlands, along with the associated trademark rights, from Sanofi, a media release says.

The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas, where the company has a leading position, with high-quality products that are innovative or unique in the market. This acquisition will enhance Lupin's Respiratory business in Germany, by aiding in the expansion of the newly established franchise, following the introduction of Luforbec.

Dr Fabrice Egros, President, Corporate Development, Lupin said, “This acquisition will strengthen our global position in treating patients suffering from diverse respiratory diseases and conditions, and it adds accretive assets in gastro-intestinal care that broaden our portfolio of branded products. We are committed to provide our customers and patients with the best products and services in the market segments where we are present, improving the quality of life for millions of people around the world.”

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the US by prescriptions. The company invested 7.8% of its revenue in research and development in FY24.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognised as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.